BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers

The Rain Foundation announced a $5 million grant program to support developers and creators worldwide in...

Related news

ENLVEnlivex Therapeutics2026-05-27 13:00 EST

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

ENLVEnlivex Therapeutics2026-06-02 13:00 EST

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-30 13:00 EST

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-29 13:00 EST

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States